AstraZeneca Fined $73m By European Commission For Misuse Of European Patent Rules
On June 15, the European Commission ("Commission") announced that it had fined Anglo-Swedish pharmaceutical company, AstraZeneca, 60 million (approx. US$73 million) for misusing the patent system, and the procedures for marketing pharmaceuticals, to block or delay market entry for generic competitors to its ulcer drug Losec. The Commission decided that AstraZeneca's actions constituted serious abuses of its dominant market position in violation of the European Union's competition rules. The level of the fine took into account that some features of the abuses were considered novel by EU standards.
Continue Reading...